PT  - JOURNAL ARTICLE
AU  - Matthew Neame
AU  - Octavio Aragon
AU  - Ricardo M Fernandes
AU  - Ian Sinha
TI  - Salbutamol or aminophylline for acute severe asthma: how to choose which one, when and why?
AID  - 10.1136/archdischild-2014-306186
DP  - 2015 Aug 01
TA  - Archives of disease in childhood - Education & practice edition
PG  - 215--222
VI  - 100
IP  - 4
4099  - http://ep.bmj.com/content/100/4/215.short
4100  - http://ep.bmj.com/content/100/4/215.full
SO  - Arch Dis Child Educ Pract Ed2015 Aug 01; 100
AB  - Acute, severe exacerbations of asthma present a challenge due to the significant morbidity associated with this presentation. For exacerbations that are refractory to initial treatments with inhaled and oral therapies, there is still doubt about which intravenous therapies are most likely to be helpful. β-2 agonists and aminophylline have differing mechanisms of action that also affect their adverse effects profiles and these are considered. A review of the available randomised control trials suggests that a bolus of intravenous salbutamol may reduce symptoms and hasten recovery. Aminophylline infusions may improve lung function, and in some studies have been shown to improve symptoms, but the evidence is not clear cut. Decisions about which treatment to use should include risk management considerations such as ease of prescription, preparation and administration factors and availability of high-dependency beds.